FDA Accepts Biohaven's Vyglxia NDA Resubmission, Sets Q1 2027 Goal Date and Advisory Committee
BHVN sits 55% above its 52-week low of $7.48.
Summary
The FDA accepted Biohaven's resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia as a complete response to the November 2025 action letter, assigning a user fee goal date in the first quarter of 2027 and planning an advisory committee meeting.
Key Events · Product Development and Regulatory · BHVN
-
FDA Accepts Troriluzole Resubmission
The FDA accepted Biohaven's NDA resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia for review, with the resubmission including new positive supportive analyses.
-
Complete Response to 2025 Action Letter
The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter.
-
Q1 2027 User Fee Goal Date
The FDA assigned a user fee goal date in the first quarter of 2027; the agency may still extend review or issue another complete response letter.
-
Advisory Committee Planned
The FDA plans to convene a Peripheral and Central Nervous System Advisory Committee meeting, with the anticipated date to be announced in the near term.
Analysis · BHVN · Life Sciences
Biohaven's lead asset is back in play. The FDA has accepted the troriluzole resubmission for spinocerebellar ataxia as a complete response to the November 4, 2025 action letter, resetting the clock on a decision with a user fee goal date in the first quarter of 2027. An advisory committee is also planned, so the path to approval now runs through an external panel whose date is still to be announced. For a company whose stock already took a hit from the September partial clinical hold on BHV-7000, a clean acceptance of the resubmission removes the immediate regulatory limbo on the SCA program and puts a concrete decision window on the calendar.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHVN was trading at $11.61 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $7.48 to $18.57. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.